Clinical Trial Update: Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a combination of daratumumab, venetoclax, and dexamethasone for newly diagnosed light-chain amyloidosis with translocation t(1…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Light-chain Amyloidosis

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Light Chain (AL) Amyloidosis | Phase 2 | Status: RECRUITING